Introduction
Butyric acid and its derivatives have been shown to inhibit growth and induce differentiation of hematopoietic and epithelial cells. These effects are correlated with altered expression of a number of cellular growth and regulatory genes. [1] [2] [3] [4] [5] In addition, both butyric acid and its monosaccharide ester derivatives induce apoptosis in certain hematopoietic cell lines, including HL60, U937, and the Burkitt's lymphoma cell line BL-30. 6 In the case of HL-60 and U937, onset of apoptosis also correlated with cell cycle arrest in G1 with induction of monocytic differentiation. In addition to modulation of growth regulatory genes, butyrate exposure has induced expression of hsp70 heat shock protein mRNA 6 and has been associated in other studies with a decrease in expression of the anti-apoptosis protein, bcl-2. 7 The chronic myelogenous leukemia cell line K562 which expresses the p 210 bcr-abl fusion protein, is known to be resistant to drug-induced apoptosis. 8 In recent studies, McGahon demonstrated that inhibition of p 210 bcr-abl gene expression using antisense oligonucleotides restored the sensitivity of K562 cells to apoptosis after exposure to chemotherapeutic agents. 9 These results suggest that bcr-abl, like bcl-2, has an anti-apoptosis function, and that overexpression of the bcr-abl protein in K562 cells and leukemia cells from patients with chronic myelogenous leukemia (CML) may in part account for the resistance of these cells to the induction of programmed cell death, therefore leading to the accumulation of leukemic blasts in patients with CML.
Since butyrate derivatives have been demonstrated to induce apoptosis in selected leukemia cells and to modulate bcl-2 expression, we hypothesized that butyrate might decrease p 210 bcr-abl expression in K562 cells and potentially in bcr-abl overexpressing chronic myelogenous leukemia cells, thereby rendering them more sensitive to apoptotic stimuli. Arginine butyrate is a butyrate salt which has been utilized in clinical studies of hemoglobinopathies and has been shown to induce globin gene synthesis in vitro and in vivo. 10 We now report that exposure of p 210 bcr-abl overexpressing leukemia cells to concentrations of arginine butyrate known to be physiologically achievable in vivo can induce apoptosis of the cells, and that this effect is concordant with a decrease in p 210 bcr-abl mRNA, protein and abl tyrosine kinase activity.
Materials and methods
Cells and culture conditions K562 cells were obtained from ATCC (Rockville, MD, USA) and were maintained by serial passage in RPMI 1640 medium supplemented by 10% heat-inactivated bovine serum (Gibco-BRL), 50 g/ml streptomycin, 50 IU/ml penicillin, and 2 mM glutamine in a 5% humidified CO 2 atmosphere at 37°C. Human leukemia cells from patient GS were isolated from whole blood by Ficoll-Hypaque separation and cell viability measured by trypan blue exclusion. Arginine butyrate stock solutions were obtained from S Perrine (Boston University Medical Center, Boston, MA, USA) and were diluted to final concentrations in tissue culture media.
Cytotoxicity assays
Exponentially growing cells were plated into 96-well plates at a final concentration of 10 4 cells/ml and were incubated with, or without arginine butyrate for 24-96 h. Cytotoxicity was measured by MTT assay (Sigma, St Louis, MO, USA). Cytotoxicity was defined as the ratio of viable cells in the drug exposed cultures compared to control cultures. Apoptosis was identified morphologically on Wright-Giemsa-stained cytospins and was characterized by cytoplasmic condensation and chromatin fragmentation. 11, 12 Cell viability was also measured by analysis of forward light scatter vs side light scatter by flow cytometry. 13 Untreated and butyrate treated cells were fixed in 70% ethanol for 30 min on ice and analyzed by FACS-SCAN (Becton Dickinson, Mountain View, CA, USA). Histograms represent ungated data.
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DNA fragmentation assays
Quantitative measurement of DNA fragmentation was made by diphenylamine colorimetric determination.
14 Butyratetreated and untreated cells were harvested by centrifugation at 200 g for 10 min and washed with PBS. The cell pellet was lysed with 0.5 ml of hypotonic buffer (10 mM Tris, 1 mM EDTA, 0.2% Triton X-100) at 4°C and the fragmented DNA was separated from chromatin by spinning the lysate at 13 000 g for 10 min at 4°C. The supernatant was removed and pellet was resuspended in 0.5 ml of hypotonic buffer. DNA from both the pellet and supernatant was precipitated overnight at 4°C in 12.5% trichloroacetic acid. Samples were spun at 13 000 g for 4 min, supernatants were discarded and 0.5 ml 0.5 N perchloric acid added to the pellets. DNA was hydrolyzed by incubation 90°C for 10 min in 80 l 5% trichloroacetic acid and the amount of DNA was quantitated colorimetrically by determining absorbance at 600 mM.
Agarose gel electrophoresis
Size characterization of fragmented DNA was performed by agarose gel electrophoresis. Cells were harvested, pelleted at 1500 r.p.m. for 5 min, washed twice with PBS and resuspended in 40 l of lysis buffer (10 mM EDTA, 50 mM Tris-HCl, pH 8.0, 0.5% SDS, 0.5 mg/ml proteinase-K). The mixture was vortexed and incubated overnight at 37°C followed by addition of 3 l of 10 mg/ml DNAse-free RNase-A. After RNA was digested at 50°C for 3 h, electrophoresis was performed on a 2% agarose gel at 22 V overnight in TBE buffer (0.09 M Tris borate, 0.002 M EDTA, pH = 8.0) containing 3 l of 10 mg/ml ethidium-bromide per 100 ml of buffer volume. Gels were photographed under UV light using Polaroid type 667, 3000 ASA film.
Western immunoblots of phosphotyrosine-containing protein
Cells were treated with varying concentrations of arginine butyrate (0.25, 0.5, 1 mM) for 0-72 h. Cells were lysed in Laemmli's sample buffer 15 containing 100 m sodium orthovanadate and resolved by SDS-PAGE (10%), transferred on to a PVDF membrane, and phosphotyrosine containing proteins detected using horseradish peroxidase-conjugated anti-phosphotyrosine antibody PY20 (Transduction Laboratories, Lexington, KY, USA) (1:2000) for 4 h, washed with 20 mM TrisHCl (pH 7.5), 150 mM NaCl and 0.05% Tween 20, and detected using the ECL chemoluminescence system (Amersham).
For detection of p 210 bcr-abl proteins, immunoblots were incubated with AB-2 antibody (Oncogene Sciences, Arlington, IL, USA) at a dilution of 1:1000 for 4 h. The blots were then washed with 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.05% Tween 20, and developed with goat anti-mouse antibody coupled to horseradish peroxidase for 1 h, followed by ECL chemoluminescence (Amersham). p 210 bcr-abl and Jak-1 autophosphorylation reactions Cells were treated with arginine butyrate for 48-72 h and then lysed in buffer containing 1% Triton X-100, 150 mM NaCl, 0.05% SDS, 10 mM Na 2 HPO 4 -NaH 2 PO 4 , pH 7.0, 100 m sodium orthovanadate, 10 g/ml leupeptin, 10 g/ml aprotinin. The lysates were incubated overnight with 5 g/ml AB-2 (Oncogene Science, Santa Cruz, CA, USA) or 1 g/ml anti-JAK-1 antibody (Santa Cruz), washed, and incubated 4 hours with 5 g/ml goat anti-mouse IgG (Sigma). Immune complexes were collected on protein A-sepharose (Pharmacia) that had been presaturated with normal serum for 4 h at 4°C, and washed three times with lysis buffer. Kinase assays were performed by incubation of immune complexes in 25 l kinase buffer containing 20 mM HEPES buffer (pH 7.0) and 10 mM MnCl 2 . Phosphorylation reactions were initiated by adding ␥-32 ATP (5 Ci) (Dupont NEN, Boston, MA, USA) for 10 min at 30°C and were terminated by addition of 25 l of 2 × Laemmli's sample buffer. Proteins were analyzed by 8% SDS-PAGE gels. Autoradiography was performed using XAR film (Kodak, Rochester, NY, USA) with intensifying screens at −70°C.
p 210 bcr-abl mRNA expression
Total cellular RNA was isolated from untreated and argininebutyrate treated K562 cells using Ultraspec. Using equal amounts of RNA from each time-point, cDNA was synthesized using Moloney murine reverse transcriptase (BRL). Polymerase chain reaction (PCR) amplification of synthesized cDNA was carried out as previously described. Oligonucleotides for bcr-abl were constructed from bp 460-75 and 645-660 of the mRNA sequence and amplified a 200 bp fragment. Oligonucleotides for GAPDH were constructed from bp 388-405, and 563-582, amplifying a 194 bp fragment. The reactions were denatured for 1 min at 95°C, annealed for 2 min at 55°C, and extended at 72°C for 1.5 min in a Perkin-Elmer (Branchburg, NJ, USA) Thermal Cycler 480. PCR products were separated on 2% agarose gels containing ethidium bromide and were photographed under UV light.
Results
Arginine butyrate inhibits growth of K562 cells
When K562 cells were exposed to arginine butyrate at concentrations from 0.1 to 1 mM, clear inhibition of cell growth, as determined by MTT assay, was observed, even at concentrations less than 0.5 mM, with greater than 80% inhibition at butyrate concentrations above 0.5 mM, (Figure 1 ). At a concentration of 0.5 mM arginine butyrate growth inhibition was seen at 24-48 h after exposure. Cellular morphology was examined by Wright-Giemsa-stained cytospins of treated cells. After 48 h of butyrate exposure, the cells demonstrated increased cell size and evidence of early chromatin clumping and cell fragmentation (not shown); at 72 h, chromatin clumping, cell shrinkage and apoptotic blebbing were noted in at least half of the cells treated with 0.5 mM arginine butyrate and fewer cells treated at lower butyrate concentrations (data not shown). As shown in Figure 1 , about 10% of the cells were viable after butyrate treatment even at high concentrations of 1 mM, suggesting that a subpopulation may be resistant to butyrate-induced inhibition of growth.
To determine whether the effects of butyrate were reversible and whether butyrate-resistant clones could be established, butyrate was removed from the culture media after a 72 h exposure and cells were subcloned in 96-well plates in butyrate-free media for 4-7 days. No viable clones regrew after Growth inhibition of K562 cells by arginine butyrate. K562 cells were plated at a concentration of 10 4 cells/ml in microtiter plates and incubated for 48 h with varying concentrations of arginine butyrate (0-1 mM). Cell viability was analyzed colorimetrically by MTT assay and % survival calculated as described in Methods.
exposure to butyrate concentrations greater than 0.5 mM, whereas viable clones were re-established after exposure to 0.1 and, to a lesser degree, 0.25 mM butyrate (data not shown).
Induction of apoptosis by arginine butyrate
To determine directly that the changes in cellular morphology in butyrate-treated cells were evidence of apoptosis, the cells were examined by flow cytometry as described by Cotter et al. 13 Using ungated data for forward and side light scatter, FACS scan analysis of unstained cells shows a marked decrease in the foreground peak representing normal viable cells after exposure to 0.5 mM arginine butyrate for 72 h (Figure 2a) . When DNA from the treated cells was examined for apoptotic laddering by electrophoresis, the characteristic 180 bp oligosomal fragments were demonstrated after 72 h of butyrate exposure, demonstrating cleavage of DNA at internucleosomal linkages (Figure 2b ). The diphenhydramine colorimetric assay was used to more precisely quantitate the degree of DNA fragmentation 14 as a function of butyrate concentration. After 72 h of exposure to 0.1 mM butyrate, no increase in fragmented DNA was observed; 17.2% of the DNA was fragmented in the cells exposed to 0.25 mM arginine butyrate, and 63.1% in cells exposed to 0.5 mM butyrate (Table 1) .
Arginine butyrate downregulates p 210 bcr-abl protein expression and kinase activity Since p 210 bcr-abl, like bcl-2, has been suggested to play a role in susceptibility to apoptosis induced by chemotherapeutic agents, we questioned whether the observed induction of apoptosis in K562 cells was associated with alteration in p 210 bcr-abl protein or kinase activity. Western immunoblots of a time-course of arginine butyrate exposure demonstrated a decrease in p 210 bcr-abl protein expression (Figure 3a) , and parallel immunoblots using the anti-phosphotyrosine antibody PY20 show a concurrent decrease in the phosphorylated p 210 species as well as minor changes in other phosphorylated pro- teins at 48 h (Figure 3c) . By 72 h, there was an overall decrease in phosphotyrosine species. To confirm equal protein loading in each lane, a Coomassie blue stained gel is shown in Figure 3b .
To determine whether similar results might be obtained from fresh leukemia cells, we exposed freshly harvested leukemic blasts from a patient with Ph chromosome-positive chronic myelogenous leukemia in blast crisis to arginine butyrate under identical conditions. Western immunoblots of the patient cells demonstrated a decrease in p 210 bcr-abl protein similar to that observed in the K562 cells (data not shown). In vitro kinase assays were performed on protein % DNA fragmentation = {A 600 nM supernatant fraction (fragmented DNA)/A 600 nM supernatant fraction (fragmented DNA) + A 600 nM pelleted DNA (unfragmented DNA)} × 100. DNA was prepared as described.
14 immunoprecipitated with AB-2 antibody and show diminution of the p 210 bcr-abl kinase activity in both the patient cells (Figure 4a, lanes 1-4) and the K562 cells (lanes 5-8) 48-72 h after exposure to 0.5 mM arginine butyrate, parallel to the decrease in protein observed by immunoblotting. To determine whether the effect of butyrate on bcr-abl tyrosine kinase activity might reflect a generalized inhibition of tyrosine kinase activity, we performed parallel in vitro kinase assays using antibodies to JAK-1 kinase, a constitutively active signalling kinase present in K562 cells. As shown in Figure 4b , no inhibition of p 130 JAK-1 kinase activity was observed after exposure of K562 cells to arginine butyrate.
To clarify whether the observed effects of arginine butyrate on p 210 bcr-abl protein and kinase represented a post-translational effect or a result of transcriptional inhibition, we analyzed mRNA expression of bcr-abl in the treated cells. Polymerase chain amplification of reverse-transcribed RNA demonstrated that bcr-abl mRNA levels decreased after butyr- 
Discussion
Arginine butyrate inhibits growth of K562 cells and induces apoptosis in a concentration-dependent fashion, with the appearance of DNA fragmentation and morphologic changes characteristic of apoptosis after 48-72 h of continuous exposure to a low concentration (0.5 mM) of arginine butyrate. Although butyrate and its analogs have been demonstrated to have a multitude of effects on cells, inducing expression of certain genes while inhibiting expression of others, the induction of apoptosis in the presence of arginine butyrate in K562 cells is associated with a decrease in expression of the antiapoptosis gene product, p 210 bcr-abl. The anti-proliferative effects of butyrate on fresh human leukemia cells were first reported by Novogrodsky et al 16 who investigated the capacity of a number of agents to induce differentiation in these cells and noted a dose-dependent inhibition of growth after exposure to sodium butyrate. They reported 50% survival of fresh leukemia cells after 72 h of exposure to 1 mM butyrate. Cell vacuolization and nuclear disintegration suggestive of apoptosis were observed in the treated cells. Novogrodsky further reported a partial remission of acute myelogenous leukemia in a child treated with parenteral butyrate, with an elimination of myeloblasts from the peripheral blood and the appearance of mature myeloid cells. Miller et al 17 attempted to reproduce these effects in a pharmacokinetic study of butyrate in patients with leukemia but were unable to demonstrate a change in blast count, perhaps
Figure 5
Inhibition of p 210 bcr-abl gene expression by arginine butyrate. Expression of GAPDH (lanes 1-4) or p 210 bcr-abl (lanes 5-8) mRNA was determined by polymerase chain amplification of reversetranscribed RNA from K562 cells treated with 0.5 mM arginine butyrate for 0 (lanes 1, 5), 24 (lanes 2, 6), 48 (lanes 3, 7) or 72 (lanes 4,  8) h. Lane 1 is 100 bp ladder. GAPDH amplified fragment is 194 bp and bcr-abl fragment is 200 bp. due to the rapid plasma clearance of butyrate and resulting low plasma levels (39-59 mM).
Recent studies have confirmed the earlier observations of Novogrodsky that butyrates can induce apoptosis in selected hematopoietic and non-hematopoietic cell lines. Hague et al 18 demonstrated induction of apoptosis in seven colon cancer cell lines tested when exposed to 0.5 mM butyrate but not at concentrations less than 0.1 mM. Apoptosis was also observed after incubation of the HL-60 and U937 leukemia cell lines with a monosaccharide ester of butyric acid, monoacetone glucose-3 butyrate, and was associated with a cell cycle arrest in G1 and morphologic changes suggestive of monocytic differentiation. 6 In these experiments, DNA fragmentation was observed 4 h after incubation with the drug with a maximum effect observed at day 6. 6 Other monosaccharide prodrugs of butyrate have demonstrated similar ability to induce apoptosis of fresh myeloid leukemia cells. 19 A high concentration of butyrate (5 mM) has also been shown to induce apoptosis accompanied by an increase in the level of hsp 70 protein expression in the Burkitt lymphoma cell line BL-30 after 16 h of exposure. 7 Of interest, butyrate-induced apoptosis in HL60 cells was correlated with decrease in bcl-2 protein expression, suggesting that one mechanism for the butyrate-mediated effects observed in leukemia cells may be related to effects of butyrate on expression or function of anti-apoptosis genes.
The K562 cell line was derived from a patient with chronic myelogenous leukemia and contains the Philadelphia chromosome, a reciprocal translocation between the region of chromosome 9 containing the abl gene and the bcr region on chromosome 22, resulting in expression of a p 210 bcr-abl fusion protein and its associated tyrosine kinase activity. This translocation and associated expression of the bcr-abl fusion gene product is a characteristic feature of chronic myelogenous leukemia, 20 and the bcr-abl gene has been shown to induce leukemia in transgenic mice. 21 Bedi et al 22 demonstrated that CML blasts had a normal proliferative response to growth factors and that growth factor-independent survival was prolonged, indicating inability of the cells to undergo programmed cell death. This result has been confirmed in vitro in that K562 and other cell lines derived from patients with chronic myelogenous leukemia are relatively insensitive to most apoptotic stimuli.
Recently, bcr-abl has been identified to be an important anti-apoptotic factor. McGahon et al 9 demonstrated that susceptibility of K562 cells to apoptosis induced by serum deprivation or chemotherapeutic agents is restored in the presence of antisense oligonucleotides which downregulate bcr-abl protein expression. Further, loss of the anti-apoptotic function of p 210 bcr-abl has been demonstrated in bcr-abl mutants in which the src-homology 2 domain, GRB2 binding site, and kinase autophosphorylation domains have all been inactivated. 23 In other studies, overexpression of v-abl in growth factor-dependent cell lines has been shown to abrogate apoptosis induced by growth factor withdrawal, suggesting that the anti-apoptotic effects of overexpressed abl are likely critical for transformation. 24, 25 While our results demonstrate that arginine butyrate treatment of K562 cells results in both downregulation of p 210 bcrabl expression and induction of apoptosis, it is unclear whether these events are independent or causally related. In McGahon's experiments using anti-sense oligonucleotides, inhibition of p 210 bcr-abl expression alone was not sufficient to initiate apoptosis but rather enabled the cells to undergo apoptosis in the presence of a trigger for apoptosis, such as cytotoxic chemotherapeutic agents. 9 In other studies in which 935 antisense oligonucleotides to bcr-abl were introduced into the murine cell line B10 rendered interleukin-3 independent by transfected bcr-abl, cell death occurred in the absence of growth factor, presumably by induction of apoptosis, whereas the same antisense constructs introduced into K562 cells inhibited p 210 expression but not proliferation, reiterating that suppression of bcr-abl expression alone is not sufficient to induce cell death in factor-independent cell lines. 26 Recently, it has been demonstrated that the antiproliferative and cytotoxic effects of antisense oligonucleotides in these experiments may not have been related to specific targeting of bcr-abl expression but to generation of toxic 5-monophosphate deoxyribonucleosides in culture medium by exonucleases. 27, 28 In our studies, butyrate induced apoptotic changes in the cells concordant with its inhibition of p 210 bcr-abl expression. It is unclear whether the effects of butyrates to modulate p 210 bcr-abl expression are alone sufficient to induce apoptosis, since butyrates can induce apoptosis in other hematopoietic cell lines not expressing p 210 bcr-abl. Butyrates may also be modulating other apoptosis effectors in the cell. The mechanisms by which butyrates trigger apoptosis in hematopoietic cells are unknown. Butyrate and its derivatives are capable of modulating expression of a number of differentiation genes, including alkaline phosphatase, peptide hormones and the globin genes without affecting viability of normal cells, and it is speculated that these effects may be mediated by histone hyperacetylation, thereby allowing for transcription of inactivated genes. 1, 10, 29 Butyrates have also been shown to alter cell cycling by inducing a G1 arrest and inhibiting accumulation of late G1-related genes, including p53, thymidine kinase and cdc2. 30 These effects are reversible upon removal of butyrate and therefore are unlikely to contribute to the induction of apoptosis in K562 and in other hematopoietic cell lines.
Recently Santini et al 19 reported that the butyrate monosaccharide ester, MAG=3 induced apoptosis in HL60 cells without overexpression of the known apoptotic regulatory genes, c-myc and p53, but with decrease in bcl-2 expression. Perhaps the induction of apoptosis in HL60, K562, and other cell lines expressing anti-apoptosis genes represents a selective sensitivity of these cells to the effects of butyrates to modulate expression of genes important in cellular homeostasis. It is unclear whether butyrates influence the expression or activity of positive regulators of apoptosis such as proteases and endonucleases.
Given the chemotherapy-refractory quality of p 210 bcr-abl expressing chronic myelogenous leukemia blasts, new approaches targeting the apoptotic blockade in these cells may be of clinical uility. Our results suggest that arginine butyrate at concentrations of 0.2-0.5 mM, which have been shown to be clinically achievable in prior clinical studies, may be useful either alone or along with cytotoxic agents in the therapy of chronic myelogenous leukemia or acute leukemias demonstrating p 210 bcr-abl overexpression. We have reported results of phase I studies using two butyrate analogs, arginine butyrate and isobutyramide in patients with refractory neoplasms and have demonstrated that plasma levels of 0.5 mM can be achieved without undue toxicity. 31, 32 Of significance, there was no evidence of myelosuppression in these studies, even at the higher dose levels, suggesting that there is no significant in vivo effect of these butyrate analogs on hematopoietic progenitor cells and that selective targeting of leukemic blast cells in patients may be feasible.
